FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094338930> ?p ?o ?g. }

• W2094338930 abstract "Definitive chemoradiotherapy (dCRT) has recently become one of the most effective therapies for the treatment of esophageal squamous cell carcinoma (ESCC). However, it is also true this treatment has not been effective in all patients. Therefore, it is very important to evaluate the surrogate marker of dCRT in order to improve clinical outcomes of patients with ESCC. On the other hand, our previous study had suggested that murine double minute 2 (MDM2) and p16 were associated with chemoradioresistance in ESCC.We selected pretreatment biopsy specimens of ESCC patients from our prospective clinical study on dCRT. Seventy-nine cases histologically diagnosed as ESCC were used. We immunohistochemically investigated these specimens using antibodies against MDM2, p53, p16, and Ki-67.The patients included 68 males and 11 females with a mean age of 63.3 years. The number of patients in each clinical stage was as follows: 22 in c-Stage I; 17 in c-Stage II; and 40 in c-Stage III. cT, cN, and cStage were significantly more advanced in the Failure group (including patients with persistent and recurrent disease after dCRT) than in the complete response (CR) group (patients with persistent CR after dCRT). The clinical stage inversely correlated with the CR rate and the rescue rate after failure. The overall survival rate was significantly worse in the patients with advanced cT, cN, and cStage levels, and in the Failure group. MDM2 positivity was significantly higher in the Failure group than in the CR group in cStageIII (P = 0.014). The number of patients with an absence of p16 immunoreactivity was significantly higher in the Failure group than in the CR group in cStageIII (P = 0.010) but not in cStageI or cStageII. Moreover, the overall survival with a Ki-67 ≥ 33.7% was significantly better than that with <33.7% for patients in cStageIII (P = 0.024).The results of this study suggested that MDM2 and p16 are predictive markers for chemoradioresistance in cStageIII ESCC and Ki-67 is a prognostic marker following dCRT in cStageIII ESCC. These issues could contribute to the formulation of treatment strategy for patients with advanced ESCC." @default.
• W2094338930 created "2016-06-24" @default.
• W2094338930 creator A5002424722 @default.
• W2094338930 creator A5003130075 @default.
• W2094338930 creator A5009042310 @default.
• W2094338930 creator A5015575554 @default.
• W2094338930 creator A5020864858 @default.
• W2094338930 creator A5024056545 @default.
• W2094338930 creator A5027841245 @default.
• W2094338930 creator A5029249568 @default.
• W2094338930 creator A5029697081 @default.
• W2094338930 creator A5035337577 @default.
• W2094338930 creator A5040635447 @default.
• W2094338930 creator A5044707863 @default.
• W2094338930 creator A5045498023 @default.
• W2094338930 creator A5076094269 @default.
• W2094338930 creator A5086895138 @default.
• W2094338930 date "2015-03-31" @default.
• W2094338930 modified "2023-09-25" @default.
• W2094338930 title "Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy" @default.
• W2094338930 cites W1968793381 @default.
• W2094338930 cites W1978633302 @default.
• W2094338930 cites W1980574258 @default.
• W2094338930 cites W1993245970 @default.
• W2094338930 cites W1995008796 @default.
• W2094338930 cites W2001103234 @default.
• W2094338930 cites W2007249806 @default.
• W2094338930 cites W2007680140 @default.
• W2094338930 cites W2019972414 @default.
• W2094338930 cites W2028282498 @default.
• W2094338930 cites W2029137678 @default.
• W2094338930 cites W2034860020 @default.
• W2094338930 cites W2037168495 @default.
• W2094338930 cites W2044182241 @default.
• W2094338930 cites W2047911091 @default.
• W2094338930 cites W2060473115 @default.
• W2094338930 cites W2066848701 @default.
• W2094338930 cites W2080121368 @default.
• W2094338930 cites W2080344286 @default.
• W2094338930 cites W2081265526 @default.
• W2094338930 cites W2084891010 @default.
• W2094338930 cites W2099907467 @default.
• W2094338930 cites W2104392448 @default.
• W2094338930 cites W2104419801 @default.
• W2094338930 cites W2107646677 @default.
• W2094338930 cites W2118305834 @default.
• W2094338930 cites W2121658595 @default.
• W2094338930 cites W2123409821 @default.
• W2094338930 cites W2147729305 @default.
• W2094338930 cites W2162614542 @default.
• W2094338930 cites W2317971897 @default.
• W2094338930 cites W2418030449 @default.
• W2094338930 cites W2598510573 @default.
• W2094338930 cites W4302044243 @default.
• W2094338930 doi "https://doi.org/10.1186/s12885-015-1222-0" @default.
• W2094338930 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4392620" @default.
• W2094338930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25880782" @default.
• W2094338930 hasPublicationYear "2015" @default.
• W2094338930 type Work @default.
• W2094338930 sameAs 2094338930 @default.
• W2094338930 citedByCount "10" @default.
• W2094338930 countsByYear W20943389302016 @default.
• W2094338930 countsByYear W20943389302018 @default.
• W2094338930 countsByYear W20943389302019 @default.
• W2094338930 countsByYear W20943389302020 @default.
• W2094338930 crossrefType "journal-article" @default.
• W2094338930 hasAuthorship W2094338930A5002424722 @default.
• W2094338930 hasAuthorship W2094338930A5003130075 @default.
• W2094338930 hasAuthorship W2094338930A5009042310 @default.
• W2094338930 hasAuthorship W2094338930A5015575554 @default.
• W2094338930 hasAuthorship W2094338930A5020864858 @default.
• W2094338930 hasAuthorship W2094338930A5024056545 @default.
• W2094338930 hasAuthorship W2094338930A5027841245 @default.
• W2094338930 hasAuthorship W2094338930A5029249568 @default.
• W2094338930 hasAuthorship W2094338930A5029697081 @default.
• W2094338930 hasAuthorship W2094338930A5035337577 @default.
• W2094338930 hasAuthorship W2094338930A5040635447 @default.
• W2094338930 hasAuthorship W2094338930A5044707863 @default.
• W2094338930 hasAuthorship W2094338930A5045498023 @default.
• W2094338930 hasAuthorship W2094338930A5076094269 @default.
• W2094338930 hasAuthorship W2094338930A5086895138 @default.
• W2094338930 hasBestOaLocation W20943389301 @default.
• W2094338930 hasConcept C126322002 @default.
• W2094338930 hasConcept C141341695 @default.
• W2094338930 hasConcept C143998085 @default.
• W2094338930 hasConcept C146357865 @default.
• W2094338930 hasConcept C151730666 @default.
• W2094338930 hasConcept C188816634 @default.
• W2094338930 hasConcept C2775934546 @default.
• W2094338930 hasConcept C2777546739 @default.
• W2094338930 hasConcept C2778424827 @default.
• W2094338930 hasConcept C2780140570 @default.
• W2094338930 hasConcept C2994415158 @default.
• W2094338930 hasConcept C509974204 @default.
• W2094338930 hasConcept C535046627 @default.
• W2094338930 hasConcept C71924100 @default.
• W2094338930 hasConcept C86803240 @default.
• W2094338930 hasConcept C90924648 @default.
• W2094338930 hasConceptScore W2094338930C126322002 @default.
• W2094338930 hasConceptScore W2094338930C141341695 @default.

• next